The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
mBio · 28.02.2023 · 14 (1)
DOI: 10.1128/mbio.02815-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 28.02.2023. Verfasst von Dirk Jochmans und 24 weiteren Autor:innen. Beteiligte Einrichtung: KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Paxlovid is the first oral antiviral approved for treatment of SARS-CoV-2 infection. Antiviral treatments are often associated with the development of drug-resistant viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium.
- Aligos Therapeutics, Inc., South San Francisco, California, USA.
- CISTIM Leuven vzw, Leuven, Belgium.
- KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Clinical & Epidemiological Virology, Leuven, Belgium.
- Institute of Virology and Immunology, University of Bern, Bern, Switzerland.
- Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
ORCID-Profile: Dirk Jochmans, Bert Vanmechelen, Piet Maes, Johan Neyts
Zitieren
APA
Jochmans, D., Liu, C., Donckers, K., Stoycheva, A., Boland, S., Stevens, S. K., De Vita, C., Vanmechelen, B., Maes, P., Trüeb, B., Ebert, N., Thiel, V., De Jonghe, S., Vangeel, L., Bardiot, D., Jekle, A., Blatt, L. M., Beigelman, L., Symons, J. A., …, & Vandyck, K. (2023). The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. mBio, 14(1). https://doi.org/10.1128/mbio.02815-22
Vancouver
Jochmans D, Liu C, Donckers K, Stoycheva A, Boland S, Stevens SK, et al. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. mBio. 2023;14(1). doi:10.1128/mbio.02815-22
BibTeX
@article{Jochmans2023,
author = {Jochmans, Dirk and Liu, Cheng and Donckers, Kim and Stoycheva, Antitsa and Boland, Sandro and Stevens, Sarah K and De Vita, Chloe and Vanmechelen, Bert and Maes, Piet and Trüeb, Bettina and Ebert, Nadine and Thiel, Volker and De Jonghe, Steven and Vangeel, Laura and Bardiot, Dorothée and Jekle, Andreas and Blatt, Lawrence M and Beigelman, Leonid and Symons, Julian A and Raboisson, Pierre and Chaltin, Patrick and Marchand, Arnaud and Neyts, Johan and Deval, Jerome and Vandyck, Koen},
title = {The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir},
journal = {mBio},
year = {2023},
volume = {14},
number = {1},
doi = {10.1128/mbio.02815-22}
}
EUVIMED